Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Variolin B
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
Variolin B is a natural product isolated from the sponge *Kirkpatrickia variolosa*, found in Antarctica. It is a potent pro-apoptotic agent and acts as a cyclin-dependent kinase (CDK) inhibitor. Variolin B has shown anti-cancer activity by inducing apoptosis and cell cycle perturbations in various cancer cell lines. It does not appear to be dependent on p53 status for its cytotoxic effects[2][3].
- Other names
- Variolin B5-(2-Aminopyrimidine-4-yl)-9-aminopyrido[3′,2′:4,5]pyrrolo[1,2-c]pyrimidine-4-ol4-Amino-8-hydroxy-9-(2-amino-4-pyrimidinyl)-3,4a,5-triaza-4aH-fluorene[6]
02
Targets
CDK1 (Cyclin-dependent kinase 1)CDK4 (Cyclin-dependent kinase 4)CDK7CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on Variolin B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Variolin B.